Clinical Efficacy and Safety of Xiao'er Baotaikang Granules in Adjuvant Treatment of Acute Upper Respiratory Tract Infection in Children
Objective To study the clinical efficacy and safety of Xiao'er Baotaikang granules in adjuvant treatment of acute upper respiratory tract infection in children.Methods A total of 68 children with acute upper respiratory tract infection diagnosed and treated in our hospital from May 2021 to April 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 34 children in each group.The control group was treated with conventional western medicine,and the observation group was treated with Xiao'er Baotaikang granules on the basis of the control group.The clinical efficacy,disappearance time of clinical symptoms(fever,cough,nasal congestion,runny nose,sore throat),levels of inflammatory factors[C-reactive protein(CRP),interleukin-18(IL-18),interleukin-6(IL-6)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group(94.12％)was higher than that of the control group(82.35％)(P＜0.05).The disappearance time of fever,cough,nasal congestion,runny nose and sore throat in the observation group was shorter than that in the control group(P＜0.05).The levels of CRP,IL-18 and IL-6 in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusion Xiao'er Baotaikang granules has a definite clinical effect in the adjuvant treatment of acute upper respiratory tract infection in children,which can improve the therapeutic effect,reduce the level of inflammatory factors,shorten the disappearance time of clinical symptoms,and does not increase adverse reactions.It has good safety and feasibility and is worthy of clinical application.
万方数据
维普
